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major violation was found as 7 out of 51 cases. By contrast, 
there were no major violation and one minor violation in 
Arm2. 
 
Conclusion: This ICR study with KROG-0806 showed the 
satisfactory protocol compliance in IMN irradiation and the 
major violation from several cases of IMN non-irradiation 
group. Quality assurance process using ICR is needed to 
evaluate and improve the quality of clinical trial in the field 
of radiation oncology. 
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Purpose or Objective 
Quality assurance of radiotherapy clinical trials ensures 
protocol compliance and robustness of outcome data. 
Benchmark cases are used to assess consistency of outlining 
and planning by different centres, and provide feedback 
before a centre starts recruitment. For a complex technique 
such as liver SBRT, it also facilitates sharing of best practice 
and supports centres with less experience. 
 
Material and Methods: The planning benchmark case was a 
large (6cm) cholangiocarcinoma with target and organ-at-risk 
contours already outlined. This case was sent to all centres 
interested in joining the ABC-07 multicentre phase II trial 
(Addition of stereotactic body radiotherapy to systemic 
chemotherapy in locally advanced biliary tract cancers; CRUK 
A18752; Sponsor University College London). Centres were 
asked to produce a plan with prescription dose of 50Gy in 5 
fractions, having PTV coverage D95% > 95% (optimal, 90% 
mandatory) and mean liver dose < 13Gy. If this was not 
possible, the prescription dose was reduced to 45Gy in 5 
fractions and mean liver dose limit increased to 15Gy. 
 
Results: 14 cases were submitted, covering a range of 
planning systems and treatment platforms. 5/10 VMAT, 1/1 
IMRT and 0/3 Cyberknife plans were able to cover 95% of the 
PTV with ≥90% of 50Gy, whilst maintaining the mean liver 
dose below 13Gy, as shown in the table. 
 
 
 
Conclusion: Achieving the planning objectives for this case 
was challenging and only 5/12 centres submitted an optimal 
plan. The other 7 centres are repeating the exercise after 
feedback on what was achievable with similar equipment. 
Achieving the optimal plan for this case involved reduced 
conformity of medium doses in order to spare other parts of 
the liver, and thereby reducing the total mean liver dose. 
This approach is contrary to typical Cyberknife planning, so it 
may not be the optimum treatment platform for these cases, 
although it is possible that differences between technologies 
and centres were accentuated by this large and challenging 
case, and may be reduced for smaller lesions. All patients 
treated within this trial will be prospectively reviewed, which 
will further inform this question. 
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Purpose or Objective: Icon enables fractionated stereotactic 
radiotherapy using a frameless patient positioning system 
(PPS). For submillimetre precision, the planning MRI scans are 
registered to a CBCT scan set acquired using Icon. Patient 
position is then adjusted using the Icon scan. Movement is 
monitored using an Intra Fraction Motion Management (IFMM) 
system.  
This presentation reports on the commissioning of Icon plus 
baseline and ongoing QA measurements.  
This is the first use of Icon in the UK. 
 
Material and Methods: CTDI was assessed for both the low 
and high dose settings and image quality checked using 
CatPhan. kVp measurements were made and dose to the 
imager assessed to confirm the Elekta presets and baseline 
values. 
A new Focus Precision Check tool containing diodes and ball 
bearings was used to ensure the accuracy of the PPS relative 
to the radiation focus and CBCT image positions.  
The IFMM system was verified using a moveable phantom. A 
reflector was attached to the phantom and moved 
independently in the x,y and z directions in 0.5 mm steps.  
If the IFMM monitored position is outside tolerance for more 
than 2 seconds, the treatment pauses and the couch is 
retracted. Treatment resumes following a re-scan, with the 
plan recalculated on the new CBCT reference. To test this 
system an output measurement was interrupted using a 
remotely moved reflector.  
An end-to-end check on a fractionated pituitary plan was 
made. The plan was recalculated on a CBCT scan of the 
spherical solid water phantom containing inserts for chamber 
and film. A film was positioned at the central axis with 2 
additional films displaced 5 & 10 mm above and below. 
 
Results: The Icon system performed within specification. 
Patient doses were acceptable and image quality resulted in 
good registration with the MRI scan sets.  
Ongoing QA results were highly reproducible demonstrating 
positioning ability of the system to within 0.5 mm. The IFMM 
readout agreed with the independent system to within 
0.04mm and repositioning following interruption had no 
significant effect on the diode doserate. The end to end film 
dosimetry agreed to within ±3% of the planned dose.  
The Icon system has allowed us to use new clinical pathways 
with little loss in positional accuracy including:  
(a) Single fraction patients who would not tolerate a fixed 
frame.  
(b) Fixed frame patients who have their CT scan with Icon.  
(c) Fractionated patients. 
 
Conclusion: Icon is an efficient system which has enabled the 
delivery of fractionated stereotactic radiotherapy plus 
improvements for single fraction patients. Accuracy is 
comparable with fixed frame treatments. 
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Purpose or Objective: Heavy metal nanoparticles (NPs) have 
been widely investigated within x-ray radiotherapy as 
radiosensitisers, where gold NPs (GNPs) have been deemed to 
be effective at enhancing the dose to the tumour. Few 
studies have been carried out for protons, where an 
extensive investigation of the enhancing factors needs to be 
carried out to determine the implications that introducing 
GNPs can have on known dose profiles. In the present work, 
we demonstrate our model which uses Geant4 to carry out 
Monte Carlo simulations of NP concentrations being irradiated 
by a proton beam. These simulations offer an indication as to 
